SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech Inc. ($MTEX) is currently trending with strong community interest, fueled by its notably low public float and increasing buying momentum. Traders are actively anticipating a significant breakout and a potential short squeeze, eyeing key price levels as volume continues to build.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is commanding market attention as a critical year-end deadline approaches for its Austin robotaxi service to operate without safety monitors, serving as a pivotal test for its AI and autonomous driving ambitions. The community is intensely divided; bulls foresee a significant rebound driven by anticipated breakthroughs in FSD and robotics, while bears highlight concerns over slowing EV demand, recent battery supply contract cuts, and a valuation heavily reliant on unproven future promises. With upcoming delivery reports also on the horizon, the market's focus remains squarely on these near-term developments to gauge the company's trajectory beyond its traditional automotive segment.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending as discussions intensify around its near-term regulatory decision for Relacorilant for Cushing's syndrome and the promising trial outcomes for its ovarian cancer and ALS programs. The community anticipates these pipeline advancements will unlock substantial future revenue, positioning the company for significant growth and prompting speculation about a potential short squeeze given its high short interest. This outlook is further supported by updated analyst price targets reflecting optimism about Corcept's expanding therapeutic impact.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to compelling preliminary Phase 3 trial data showing an 80% reduction in breast cancer recurrence, alongside a significant show of insider confidence with the Board extending share lock-ups until September 2026. This news has intensified community discussions around a potential short squeeze, given the stock's extremely low float and high cost to borrow, as investors anticipate substantial upside for this undervalued immunotherapy company.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is generating significant buzz as China's recent sanctions are being interpreted by many in the community as a "badge of honor" validating the company's strategic defense role, particularly concerning Taiwan. This development, coupled with the imminent U.S. FCC ban on foreign-made drones, is fueling anticipation for major contracts, though some investors express frustration over past guidance and executive stock transactions.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem is currently a hot topic after discontinuing its RAMP 203 trial to focus on the promising VS-7375 program, a strategic pivot that followed strong Q3 revenue beats. However, a recent $90 million public offering has sparked considerable frustration and debate among investors, many of whom feel betrayed by the dilution despite the company's stated financial position. This has led to accusations of market manipulation and amplified concerns about short selling within a volatile biotech sector.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is a major talking point following a proposed business combination with Applied Digital's AI cloud division, ChronoScale, which aims to create an accelerated compute platform. The community is buzzing about this strategic pivot, with strong sentiment around its NVIDIA program acceptance and newly reduced share float amplifying expectations for significant future growth in the artificial intelligence space. Many believe the company is currently undervalued and poised for a substantial rally.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies (AMPX) is trending amid a leadership transition to a new CEO focused on scaling production, an expanded South Korea manufacturing alliance, and new partnerships like Nokia's battery integration. Despite a significant stock decline, which some attribute to broader small-cap market pressure and speculation of manipulation, the community maintains strong long-term conviction. Investors point to the company's advanced battery technology and potential for major contracts in defense and aerospace, including widespread discussion of Amazon's drone and satellite programs, as key drivers for future growth.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

Sprott Physical Silver Trust (PSLV) is trending as the community anticipates a significant silver squeeze, fueled by an impending China export ban and surging industrial demand for AI, EVs, and solar. Investors are increasingly concerned about the divergence between paper and physical silver prices, believing years of manipulation are breaking, positioning PSLV for a substantial, generational bull run as silver gains recognition as a critical global commodity.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical ($RARE) is trending due to a significant sell-off following the unexpected failure of its late-stage setrusumab trial for brittle-bone disease to meet its primary endpoint. This news has sparked a heated community debate, with many investors questioning if the steep stock decline is an overreaction given Ultragenyx's existing portfolio of four approved therapies and multiple upcoming pipeline catalysts. While some see a 'huge opportunity' for a rebound at a deep discount, others remain cautious amid the volatility typical of the biotech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


SEPZ
Listed Funds Trust - TrueShares Structured Outcome (September) ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SEPZ News

SEPZListed Funds Trust - TrueShares Structured Outcome (September) ETF